SEARCH

SEARCH BY CITATION

References

  • Anderson P, Louie J, Lau A, Broder M (2005). Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Curr Rheumatol Rep 7: 39.
  • Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR et al. (2009). Differences in binding and effector functions between classes of TNF antagonists. Cytokine 45: 124131.
  • Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S et al. (2000). Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 6: 583588.
  • Atreya R, Atreya I, Neurath MF (2006). Novel signal transduction pathways: analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease. Ann N Y Acad Sci 1072: 98113.
  • Babyatsky MW, Rossiter G, Podolsky DK (1996). Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 110: 975984.
  • Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A et al. (2003). Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348: 601608.
  • Bazzoni F, Beutler B (1996). The tumor necrosis factor ligand and receptor families. N Engl J Med 334: 17171725.
  • Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E et al. (2006). Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 55: 228233.
  • Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF et al. (1997). A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385: 729733.
  • Boirivant M, Pallone F, Di Giacinto C, Fina D, Monteleone I, Marinaro M et al. (2006). Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology 131: 17861798.
  • Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006). Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 22752285.
  • Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP et al. (2006). A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 4: 754759.
  • Brand S (2009). Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 58: 11521167.
  • Caruso R, Fina D, Peluso I, Stolfi C, Fantini MC, Gioia V et al. (2007). A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology 132: 166175.
  • Caruso R, Sarra M, Stolfi C, Rizzo A, Fina D, Fantini MC et al. (2009). Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology 136: 22702279.
  • Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R et al. (2007). Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132: 5265.
  • D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F et al. (1999). Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 116: 10291034.
  • D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y et al. (2011). The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 106: 199212.
  • Efimov GA, Kruglov AA, Tillib SV, Kuprash DV, Nedospasov SA (2009). Tumor necrosis factor and the consequences of its ablation in vivo. Mol Immunol 47: 1927.
  • Fina D, Sarra M, Fantini MC, Rizzo A, Caruso R, Caprioli F et al. (2008). Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 134: 10381048.
  • Fossati G, Nesbitt AM (2005). Effect of the anti-TNF agents, adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870) on the induction of apoptosis in activated peripheral blood lymphocytes and monocytes. Am J Gastroenterol 100 (Suppl. S): S298S299.
  • Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y et al. (2003). Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52: 6570.
  • Fuss IJ, Neurath M, Boirivant M, Klein JS, Motte C, Strong SA et al. (1996). Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157: 12611270.
  • Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S et al. (2004). Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 113: 14901497.
  • Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schaffer AA, Noyan F et al. (2009). Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 361: 20332045.
  • Gorelik L, Flavell RA (2002). Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2: 4653.
  • Gustot T, Lemmers A, Louis E, Nicaise C, Quertinmont E, Belaiche J et al. (2005). Profile of soluble cytokine receptors in Crohn's disease. Gut 54: 488495.
  • Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al. (2002). Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 15411549.
  • Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D et al. (2006). Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130: 323333.
  • Heldin CH, Miyazono K, ten Dijke P (1997). TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390: 465471.
  • Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W (2002). Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 17: 629638.
  • Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J et al. (2006). Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 55: 11311137.
  • ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ (2002). Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50: 206211.
  • Hyams JS, Fitzgerald JE, Treem WR, Wyzga N, Kreutzer DL (1993). Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology 104: 12851292.
  • Iliev ID, Spadoni I, Mileti E, Matteoli G, Sonzogni A, Sampietro GM et al. (2009). Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells. Gut 58: 14811489.
  • Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A et al. (2004). A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126: 989996.
  • Kaser A, Zeissig S, Blumberg RS (2010). Inflammatory bowel disease. Annu Rev Immunol 28: 573621.
  • Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al. (2001). Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 10981104.
  • Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G (1999). Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10: 387398.
  • Ma HL, Napierata L, Stedman N, Benoit S, Collins M, Nickerson-Nutter C et al. (2010). Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum 62: 430440.
  • MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A (1990). Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 81: 301305.
  • MacDonald TT, Bajaj-Elliott M, Pender SL (1999). T cells orchestrate intestinal mucosal shape and integrity. Immunol Today 20: 505510.
  • MacEwan DJ (2002). TNF ligands and receptors – a matter of life and death. Br J Pharmacol 135: 855875.
  • Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D et al. (2004). Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351: 20692079.
  • Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F et al. (1997). Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112: 11691178.
  • Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT (2001). Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 108: 601609.
  • Monteleone G, Monteleone I, Fina D, Vavassori P, Del Vecchio Blanco G, Caruso R et al. (2005). Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 128: 687694.
  • Monteleone G, Caruso R, Fina D, Peluso I, Gioia V, Stolfi C et al. (2006). Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 55: 17741780.
  • Monteleone I, Rizzo A, Sarra M, Sica G, Sileri P, Biancone L et al. (2011). Aryl hydrocarbon receptor-induced signals upregulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology 141: 237248.e1.
  • Moore KW, Malefyt R, Coffman RL, O'Garra A (2001). Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683765.
  • Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W (1995). Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182: 12811290.
  • Neurath MF, Fuss I, Pasparakis M, Alexopoulou L, Haralambous S, Meyer zum Buschenfelde KH et al. (1997). Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 27: 17431750.
  • Neurath MF, Weigmann B, Finotto S, Glickman J, Nieuwenhuis E, Iijima H et al. (2002). The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 195: 11291143.
  • Nishimoto N, Kishimoto T (2006). Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2: 619626.
  • Ouyang W (2010). Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. Cytokine Growth Factor Rev 21: 435441.
  • Parrello T, Monteleone G, Cucchiara S, Monteleone I, Sebkova L, Doldo P et al. (2000). Up-regulation of the IL-12 receptor beta 2 chain in Crohn's disease. J Immunol 165: 72347239.
  • Peluso I, Fantini MC, Fina D, Caruso R, Boirivant M, MacDonald TT et al. (2007). IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 178: 732739.
  • Pender SL, Breese EJ, Gunther U, Howie D, Wathen NC, Schuppan D et al. (1998). Suppression of T cell-mediated injury in human gut by interleukin 10: role of matrix metalloproteinases. Gastroenterology 115: 573583.
  • Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF (2008). Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 6: 644653.
  • Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL (1994). Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1: 553562.
  • Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA et al. (1999). Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340: 13981405.
  • Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B et al. (2006). A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 55: 11381144.
  • Reinisch W, de Villiers W, Bene L, Simon L, Racz I, Katz S et al. (2010). Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 16: 233242.
  • Rose-John S, Scheller J, Elson G, Jones SA (2006). Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 80: 227236.
  • Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al. (2005). Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 24622476.
  • Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S et al. (2008). A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135: 11301141.
  • Sands BE, Jacobson EW, Sylwestrowicz T, Younes Z, Dryden G, Fedorak R et al. (2010). Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflamm Bowel Dis 16: 12091218.
  • Schoepfer AM, Vavricka SR, Binek J, Felley C, Geyer M, Manz M et al. (2010). Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey. Inflamm Bowel Dis 16: 933938.
  • Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S et al. (2000). Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 119: 14611472.
  • Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M et al. (2005). A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129: 807818.
  • Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E et al. (1998). Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 66: 52245231.
  • Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T et al. (1997). A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337: 10291035.
  • Trinchieri G (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133146.
  • Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N et al. (2003). Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 125: 3239.
  • Watanabe T, Kitani A, Murray PJ, Strober W (2004). NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 5: 800808.
  • Weir N, Athwal D, Brown D, Foulkes R, Kollias GI, Nesbitt A et al. (2006). A new generation of high-affinity humanized PEGylated Fab' fragment anti-tumor necrosis factor-(alpha) monoclonal antibodies. Therapy 3: 535545.
  • Wollina U, Hansel G, Koch A, Schonlebe J, Kostler E, Haroske G (2008). Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 9: 114.